BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enlivex Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Enlivex Therapeutics's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07580716-106@assetmemo.bio
DTSTAMP:20261121T005927Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Allocetra: Phase 2 readout est. (NCT07580716)
DESCRIPTION:Allocetra\, phase 2\, Osteoarthritis.\nStudy: Intra-Articular A
 llocetra in Patients With Primary Knee Osteoarthritis\nEstimated primary c
 ompletion: February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/allocetra#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07580716
URL:https://assetmemo.bio/drug/allocetra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
